Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1921 to 1935 of 8990 results

  1. Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630]

    Awaiting development Reference number: GID-TA11837 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Isatuximab in combination for maintenance treatment of newly diagnosed multiple myeloma after an autologous stem cell transplant [ID6639]

    Awaiting development Reference number: GID-TA11846 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Odronextamab for treating relapsed or refractory follicular lymphoma [ID6726]

    Awaiting development Reference number: GID-TA11829 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591]

    Awaiting development Reference number: GID-TA11753 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176]

    Awaiting development Reference number: GID-TA11752 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]

    Awaiting development Reference number: GID-TA11470 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949]

    Awaiting development Reference number: GID-TA11465 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]

    Awaiting development Reference number: GID-TA11425 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]

    Awaiting development Reference number: GID-TA11404 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Concizumab for treating severe haemophilia A or moderate to severe haemophilia B in people 12 years and over without inhibitors [ID5099]

    Awaiting development Reference number: GID-TA10972 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Surovatamig for treating relapsed or refractory follicular lymphoma after 2 or more treatment lines [TSID12354]

    Awaiting development Reference number: GID-TA11976 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Remibrutinib for treating chronic inducible urticaria inadequately controlled by H1-antihistamines [ID6742]

    Awaiting development Reference number: GID-TA11968 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

    Awaiting development Reference number: GID-TA10453 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID1237]

    In development Reference number: GID-TA10239 Expected publication date:  06 August 2026

    Technology appraisal guidance
    In development

  15. Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care

    Awaiting development Reference number: GID-QS10144 Expected publication date: TBC

    Quality standard
    Awaiting development